Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer

NCT04527991 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04527991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04527991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
January 13, 2021
Completion date
July 4, 2025
Enrollment
711 (actual)
Sites
234

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic unresectable urothelial cancer